Background

Adeno-associated virus (AAV) is considered the standard vector in today's in vivo gene therapy field. This is due to the belief that it exists as episomes—independent circular DNA within the nucleus—without integrating into the host cell chromosomes. This non-integrating characteristic has been widely regarded as the core rationale for reducing the risk of insertional mutagenesis or cancer. It was generally considered that lentiviruses and retroviruses were relatively free from the genotoxicity controversies they had faced in past clinical trials.

In clinical practice, active efforts were being made to treat fatal rare neurodegenerative diseases. A representative example is Krabbe disease, a genetic disorder where nerve white matter is damaged due to galactocerebrosidase (GALC) deficiency. Since hematopoietic stem cell transplantation was insufficient to prevent central nervous system (CNS) damage, the academic community focused on therapeutic strategies to directly deliver normal genes to the brain and spinal cord using viral vectors.

While concerns regarding potential genotoxicity arose in preclinical animal studies due to the possibility of AAV genome fragments integrating into host chromosome cleavage sites, clear clinical evidence of tumors caused by viral insertion in actual human patients had not been reported to the academic community until now. This belief in a non-integrating vector underpinned the clinical field.

Key Findings

Professor Arul M. Chinnaiyan's team at the Center for Translational Pathology, University of Michigan Medical School, published the results of a precise analysis of a tumor that occurred in an AAV-treated patient in the New England Journal of Medicine (NEJM).

The subject was a three-year-old infant with Krabbe disease who received the AAVrh10 vector-based therapeutic FBX-101 after hematopoietic stem cell transplantation. Following treatment, the child was diagnosed with a paraspinal neoplasm, an abnormal mass growing around the spinal nerves. When the tumor tissue resected by medical staff was analyzed using next-generation sequencing, unexpected findings were revealed.

A pattern of AAV vector fragments being inserted into the host chromosome as a single clone was confirmed across tumor cells. This was not an accidental remnant but a key event that dominated the entire cell division process.

The inserted vector fragment contained the intact CAG promoter-enhancer region, a synthetic regulatory element added to maximize gene expression. Analysis showed that this promoter was positioned precisely in front of GLI1, a proto-oncogene that regulates cell growth and development. The transcription factor, which should have remained dormant in adult tissue, continuously received signals from the foreign promoter, leading to abnormal overexpression and ultimately resulting in tumor proliferation. This is the first empirical case demonstrating that an AAV vector directly causes oncogenic insertional mutagenesis in the human body.

Implications and Outlook

This report provides a decisive counterexample to the long-held belief that AAV does not induce chromosomal variations in humans. It marks the first demonstration within a human body that fragmented vector particles can insert into chromosomal gaps and cause lethal mutations when high doses of the virus are administered.

A complete revision of the direction of gene therapy design has also become inevitable. The development practice of using powerful, ubiquitous promoters like CAG to strongly turn on therapeutic genes is now subject to review. There are growing calls to urgently introduce safeguards that reduce activity when inserted, or to replace existing elements with tissue-specific promoters that activate selectively only in target cells.

Establishing a long-term follow-up system has also emerged as an urgent challenge. While the tumor in this case was removed via surgery, if a tumor develops in the deep parts of the nervous system that are difficult to access, it is difficult to avoid fatal consequences. This highlights the urgent need to establish guidelines mandating regular imaging examinations and molecular diagnostics after treatment.

There is no reason to stop AAV therapy itself. The neuroprotective benefits provided by gene therapy to patients with fatal rare diseases with no alternatives are immense. Now is the time for precise design that faces the risks and enhances vector safety.